- PA5-27298 - Invitrogen Antibodies AREG antibody

Submitted references In mouse chronic pancreatitis CD25(+)FOXP3(+) regulatory T cells control pancreatic fibrosis by suppression of the type 2 immune response.

Glaubitz J, Wilden A, Golchert J, Homuth G, Völker U, Bröker BM, Thiele T, Lerch MM, Mayerle J, Aghdassi AA, Weiss FU, Sendler M
Nature communications 2022 Aug 3;13(1):4502

Amphiregulin activates human hepatic stellate cells and is upregulated in non alcoholic steatohepatitis.

McKee C, Sigala B, Soeda J, Mouralidarane A, Morgan M, Mazzoccoli G, Rappa F, Cappello F, Cabibi D, Pazienza V, Selden C, Roskams T, Vinciguerra M, Oben JA
Scientific reports 2015 Mar 6;5:8812

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of Amphiregulin using 30 µg of A) IMR32 and B) U87-MG lysate. Samples were loaded onto a 12% SDS-PAGE gel and probed with an Amphiregulin polyclonal antibody (Product # PA5-27298) at a dilution of 1:1000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot analysis of Amphiregulin was performed by separating 30 µg of non-transfected (–) and transfected (+) 293T whole cell extracts by 12% SDS-PAGE. Proteins were transferred to a membrane and probed with a Amphiregulin Polyclonal Antibody (Product # PA5-27298) at a dilution of 1:3000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis of Amphiregulin was performed in paraffin-embedded human colon cancer tissue using Amphiregulin Polyclonal Antibody (Product # PA5-27298) at a dilution of 1:500.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 AR mRNA expression in hHSC. (A) Cultures of hHSC show significantly higher expression (* p < 0.05) of AR by day 4 compared to day 0. Expression is effectively reduced by day 10 (** p < 0.01). (B) AR mRNA expression is preceded by the up-regulation of the TACE gene, required for AR activity. TACE expression is highest at day 2 (*p < 0.05) and is reduced by day 4 (**p < 0.01). (C) Western blot analysis for AR and TACE protein levels in hHSC at day 0, 2, 4 and 10 (left panel); images were obtained from separate gels, run under the same experimental conditions, blotted on separate PVDF membranes and processed for detection with the respective antibodies. Densitometric quantification normalized to beta-actin levels (right panel). Images are representative of three independent experiments (* p < 0.05; ** p < 0.01). (D) TACE activities in hHSC at day 0, 2, 4 and 10 were measured using SensoLyte 520 TACE Activity Assay kit. N = 3, ** p < 0.01.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Effect of AR on collagen 1a2 production. (A) AR is capable of inducing collagen production at both picogram and nanogram concentrations (*p < 0.05). The effect is similar to that of TGF-beta, inductor of collagen production, a major step in the pathogenesis of fibrosis. (B) Mice were fed either a normal chow diet or a methionine-choline deficient (MCD) diet modelling NASH. Mice on MCD diet expressed higher hepatic AR mRNA levels than mice fed a normal chow diet (*p < 0.001). (C) Western blot analysis for AR protein levels in hepatocytes and mHSC isolated from MCD mice (left panel). Images were obtained from separate gels, run under the same experimental conditions, blotted on separate PVDF membranes and processed for detection with the respective antibodies. Densitometric quantification normalized to beta-actin levels (right panel). Images are representative of three independent experiments (* p < 0.05).

PA5-27298

Antibody data